Clinical trial data releases and regulatory milestone announcements (IND filings, Phase advancement, safety/efficacy readouts)
Capital raises and financing announcements (dilutive equity offerings, debt facilities, strategic partnerships)
Competitive developments in allogeneic T-cell therapy space (rival trial results, FDA approvals for competing platforms)
Management changes, patent developments, or manufacturing partnership announcements
moderate - Pre-revenue biotechs are partially insulated from GDP cycles as drug demand is non-discretionary, but financing availability is highly cyclical. During recessions, venture capital and public market appetite for speculative biotech diminishes, making capital raises more difficult or dilutive. Clinical trial timelines are generally GDP-insensitive, but partnership activity slows when large pharma companies reduce M&A budgets.
High sensitivity to interest rates through multiple channels: (1) Valuation - pre-revenue biotechs are valued on discounted future cash flows 5-10+ years out, making them extremely sensitive to discount rate changes. Rising rates compress NPV of distant approvals. (2) Financing costs - higher rates increase cost of debt financing and make equity raises more dilutive as investors demand higher returns. (3) Competitive cost of capital - rising rates make safer fixed-income alternatives more attractive versus speculative biotech equity. The 10-year Treasury yield directly impacts institutional allocation to high-risk growth stocks.
Clinical trial failure risk - Phase I/II assets have <15% probability of ultimate FDA approval; single negative readout could render equity worthless
Regulatory pathway uncertainty for allogeneic T-cell therapies with evolving FDA guidance on manufacturing, potency assays, and safety monitoring requirements
Reimbursement uncertainty - even with approval, payer willingness to cover novel cell therapies at profitable price points remains unproven for non-CAR-T approaches
momentum/speculative - Attracts high-risk tolerance investors seeking asymmetric returns from binary clinical events. Not suitable for value investors (no earnings/cash flow to value) or dividend investors (no distributions). Typical holders include biotech-focused hedge funds, retail speculators, and venture crossover funds. The 82% one-year decline and -38% three-month return indicate capitulation by institutional holders, leaving primarily distressed/event-driven players.
Trend
-4.5% vs SMA 50 · -70.6% vs SMA 200
Momentum
Accumulation pattern present — more buying days than selling over the past 20 sessions. Volume conditions support gradual price improvement.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $0 | — | -$7.50 | — | — | Low1 |
FY2026(current) | $0 | — | -$10.14 | — | — | Low1 |
FY2027 | $502.3M $502.3M–$502.3M | — | -$13.01 | — | — | Low1 |
INSTITUTIONAL OWNERSHIP
TVGN News
About
No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
TVGN◀ | $7.95 | -15.61% | $33M | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -4.77% | — | 50.3 | +398824.8% | -4085.6% | 1500 |